Takeda takes vaccine investment at German site beyond 200 million euros
A new 74 million euros ($88 million) plant is being built at Takeda’s (TYO: 4502) production facility in Singen, Germany.
The Japanese drugmaker is already spending 130 million euros on vaccine production at the site, where an extra 100 employees will be added to the 1,000 already based at the facility.
"Dengue is the fastest spreading mosquito-borne viral disease"Takeda’s plant is dedicated to producing the drug substance for its dengue vaccine candidate, TAK-003, and this new building means that everything from the manufacturing of the active drug substance to the production of the vaccine, to the filling and final packaging, to worldwide shipping, will take place in one location. It is hoped that this will all be up-and-running by 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze